News Sentiment

QNRX sentiment intelligence

Quoin Pharmaceuticals Ltd DRC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.24 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-4.7% over one week, -8.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Cash flow from financing activities of Quoin Pharmaceuticals. Ltd Sponsored ADR – LS:A41BEM

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -4.7% Price reacting lower
Trend fit Trend inactive -8.8% over four weeks
Fair value -90.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 32
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 7
Market source 7
Stock Titan 6
GlobeNewswire 5
Moomoo 4
MT Newswires 3
simplywall.st 3
Sahm 2

Event Lens

What the news is about

Classified themes
Market update 21
Regulatory and legal 12
Earnings 10
Analyst action 3
Balance sheet 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
TradingView Direct company coverage

Cash flow from financing activities of Quoin Pharmaceuticals. Ltd Sponsored ADR – LS:A41BEM

This article displays the cash flow from financing activities for Quoin Pharmaceuticals. Ltd Sponsored ADR (LS:A41BEM) on TradingView. It provides a placeholder for financial data ("Period Value Change Change %") related to this specific financial metric. The page is part of the

Tone
Neutral 50/100
Event
Balance sheet
Published
22 Jul 2026 09:39
Source
TradingView
Sahm Direct company coverage

Insider Traders Lose US$65k As Quoin Pharmaceuticals Drops

Insiders at Quoin Pharmaceuticals, who collectively invested US$128.6k at an average price of US$8.49 per share over the last year, have seen their investment value drop to US$63.8k due to an 11% price decline. The biggest single purchase was by Independent Director Dennis Langer

Tone
Negative 29/100
Event
Market update
Published
17 Jul 2026 12:39
Source
Sahm
TradingView Direct company coverage

Price to book forward of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0

This page provides financial information for Quoin Pharmaceuticals. Ltd Sponsored ADR (FWB:2EB0) on the Frankfurt Stock Exchange, specifically focusing on its price to book forward metric. The content indicates that the market is closed with no current trades. It also details tha

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 23:40
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0

This article displays the "Enterprise value to EBIT forward" for Quoin Pharmaceuticals. Ltd Sponsored ADR (FWB:2EB0) on the Frankfurt Stock Exchange. It indicates that the market is closed with no trades and provides a link to the financial data for the company. The rest of the c

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 20:40
Source
TradingView
Moomoo Direct company coverage

Quoin Pharmaceuticals | ARS: Annual Report to Security Holders

This article provides access to the Annual Report to Security Holders (ARS) for Quoin Pharmaceuticals. The report is a crucial document for investors and stakeholders, offering a comprehensive overview of the company's financial performance and operational activities over the pas

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 19:11
Source
Moomoo
Stock Titan Direct company coverage

Quoin Pharmaceuticals (NASDAQ: QNRX) details 2026 meeting and pay votes

Quoin Pharmaceuticals will hold its 2026 Annual General Meeting on August 20, 2026, where shareholders will vote on five key proposals, including the election of seven directors, an advisory "say-on-pay" for executive compensation, changes to director compensation, and changes to

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 11:11
Source
Stock Titan
GlobeNewswire Direct company coverage

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Quoin Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for QRX003 to treat Peeling Skin Syndrome (PSS), allowing a Phase 2 clinical study to commence in the second half of 2026. This marks the first formal clinical study for PSS, a

Tone
Positive 94/100
Event
Regulatory and legal
Published
10 Jul 2026 09:10
Source
GlobeNewswire
GuruFocus Direct company coverage

Quoin Pharmaceuticals (QNRX) Gains FDA Approval for QRX003 Clinical Trial

Quoin Pharmaceuticals (QNRX) has received FDA approval for its investigational new drug application for QRX003, intended to treat Peeling Skin Syndrome, enabling the company to proceed with Phase 2 clinical trials. The company, which focuses on rare diseases, has a strong financi

Tone
Positive 73/100
Event
Regulatory and legal
Published
09 Jul 2026 20:10
Source
GuruFocus
Quiver Quantitative Direct company coverage

Quoin Pharmaceuticals Announces FDA Clearance of QRX003 IND for Peeling Skin Syndrome, Plans Phase 2 Study in 2H 2026

Quoin Pharmaceuticals has received FDA clearance for its Investigational New Drug (IND) application for QRX003 to treat Peeling Skin Syndrome (PSS), allowing a Phase 2 clinical study to commence in the second half of 2026. This will be the first formal clinical study for PSS, enr

Tone
Positive 81/100
Event
Regulatory and legal
Published
09 Jul 2026 12:44
Source
Quiver Quantitative
Stock Titan Direct company coverage

Rare skin disease gets first company-backed clinical trial as Quoin wins FDA clearance

Quoin Pharmaceuticals has received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 2 study of QRX003 for Peeling Skin Syndrome (PSS) in the second half of 2026. This marks the first IND cleared for PSS and the first company-sponsored formal cl

Tone
Positive 82/100
Event
Regulatory and legal
Published
09 Jul 2026 12:21
Source
Stock Titan
Investing.com UK Direct company coverage

Form PRE 14A Quoin Pharmaceuticals Ltd. For: 6 July By Investing.com

This article from Investing.com announces the filing of Form PRE 14A by Quoin Pharmaceuticals Ltd. for July 6th. The content is brief and primarily focuses on this regulatory filing, indicating an informational update rather than in-depth analysis.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
07 Jul 2026 08:10
Source
Investing.com UK
Moomoo Direct company coverage

Quoin Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition

This document is a PRE 14A filing by Quoin Pharmaceuticals, indicating the submission of preliminary proxy statements related to a potential merger or acquisition. PRE 14A filings are used to notify shareholders of an upcoming vote on significant corporate actions, such as merger

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 03:11
Source
Moomoo
Market source Direct company coverage

Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome

Quoin Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering a combination treatment for Netherton Syndrome. This patent, which protects the company's investigational treatment QRX003, involves a topical serine p

Tone
Positive 81/100
Event
Regulatory and legal
Published
02 Jul 2026 08:10
Source
Market source
Finviz Direct company coverage

QNRX - Quoin Pharmaceuticals Ltd ADR Volatility & Greeks

This article provides a detailed financial overview of Quoin Pharmaceuticals Ltd ADR (QNRX), including its latest closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as volatility, RSI, beta, and histori

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 18:39
Source
Finviz
Stock Titan Direct company coverage

Quoin wins U.S. patent step for Netherton syndrome treatment

Quoin Pharmaceuticals (NASDAQ: QNRX) has received a U.S. Notice of Allowance for a patent covering a combination treatment for Netherton Syndrome, strengthening the intellectual property for its investigational topical therapy, QRX003 (QYLEKI). This patent covers a method using d

Tone
Positive 77/100
Event
Regulatory and legal
Published
30 Jun 2026 12:39
Source
Stock Titan
TradingView Direct company coverage

Quoin Pharmaceuticals. Ltd Sponsored ADR Actuals & Estimates (NASDAQ:QNRX)

This page provides an overview of Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) including its stock market information, financial actuals, and analyst estimates. Users can explore reported financial data across income statements, balance sheets, and cash flow statements, comparing a

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 09:39
Source
TradingView
Sahm Direct company coverage

Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome

Quoin Pharmaceuticals announced that the FDA has conditionally approved QYLEKI™ as the proposed brand name for QRX003, its investigational product for Netherton Syndrome. This represents a significant milestone as the company moves towards potentially delivering the first approve

Tone
Positive 81/100
Event
Regulatory and legal
Published
24 Jun 2026 15:40
Source
Sahm
TradingView Direct company coverage

Quoin Pharmaceuticals: FDA Conditionally Accepts QYLEKI as Proposed Brand Name for QRX003

Quoin Pharmaceuticals received conditional FDA acceptance for QYLEKI as the proposed brand name for QRX003, their treatment for Netherton Syndrome. This marks a significant regulatory step, with the company planning to seek final approval during the NDA process. QRX003 has multip

Tone
Positive 82/100
Event
Regulatory and legal
Published
23 Jun 2026 20:39
Source
TradingView
Moomoo Direct company coverage

Trending Stocks Today | Quoin Pharmaceuticals Shoots up 41.6% Post-Market

Quoin Pharmaceuticals (QNRX) saw a significant post-market surge of 41.6% due to substantial insider buying activity. Several key insiders acquired over 1.7 million shares at an average price of $1.16 per share, indicating strong internal confidence in the company's future prospe

Tone
Positive 81/100
Event
Market update
Published
23 Jun 2026 20:39
Source
Moomoo
Stock Titan Direct company coverage

FDA backs QYLEKI name as Quoin (NASDAQ: QNRX) advances QRX003

Quoin Pharmaceuticals announced that the FDA has conditionally approved QYLEKI™ as the proposed brand name for QRX003, its investigational lotion for Netherton Syndrome. This product holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations, with a pivotal Phase 3 st

Tone
Positive 71/100
Event
Regulatory and legal
Published
23 Jun 2026 20:39
Source
Stock Titan
Benzinga Direct company coverage

12 Health Care Stocks Moving In Tuesday's After-Market Session

This article lists 12 healthcare stocks that experienced significant movement during Tuesday's after-market session, including both gainers and losers. Notable gainers include Quoin Pharmaceuticals (QNRX) and Mobile-health Network (MNDR), while Aditxt (ADTX) and Vivos Therapeutic

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 20:39
Source
Benzinga
Stock Titan Direct company coverage

FDA conditionally approves Quoin's QYLEKI name for rare skin drug

Quoin Pharmaceuticals has received conditional FDA approval for QYLEKI as the proposed brand name for QRX003, their investigational treatment for Netherton Syndrome. This drug has multiple expedited designations and is on track for a pivotal Phase 3 study in late 2026, with a pot

Tone
Positive 70/100
Event
Regulatory and legal
Published
23 Jun 2026 12:29
Source
Stock Titan